NCT05170035 is a NA clinical trial of MMS + Autologous patch in Skin Cancer, sponsored by Bispebjerg Hospital.

Who is sponsoring NCT05170035?

NCT05170035 is sponsored by Bispebjerg Hospital.

What drugs are being tested in NCT05170035?

Interventions in NCT05170035: MMS + Autologous patch, MMS and secondary intention healing.

What condition does NCT05170035 study?

NCT05170035 studies Skin Cancer, Basal Cell Carcinoma.

Is NCT05170035 still recruiting?

NCT05170035 is currently status unknown. Last updated 15 March 2023.

Last reviewed 2023-03-15 · How we verify

NCT05170035

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Autologous Patch Healing vs. Secondary Intention Healing After Mohs Micrographic Surgery - A Randomized Controlled Trial

Status unknown NA Last updated 15 March 2023

What this trial tests

NA trial testing MMS + Autologous patch in Skin Cancer in 26 participants. Status unknown.

Timeline

1 February 2022

Primary endpoint
1 February 2024

1 February 2024

Quick facts

Lead sponsor	Bispebjerg Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	26
Start date	1 February 2022
Primary completion	1 February 2024
Estimated completion	1 February 2024
Sites	1 location across Denmark

Drugs / interventions tested

MMS + Autologous patch
MMS and secondary intention healing

Conditions studied

Skin Cancer — all drugs for Skin Cancer →
Basal Cell Carcinoma — all drugs for Basal Cell Carcinoma →

Sponsor

Bispebjerg Hospital

Who can join

Adults 18 to 100, any sex, with Skin Cancer or Basal Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Blinded assesment of wound healing at day 18-20.
Time frame: Day 18-20
Two indenpendent trained clinical doctors will evaluate clinical photos. Wounds will be evaluated fully epithelialized yes/no.

Sponsor's own description

The primary objects of this study is to explore the potential effect of the autologous patch to optimize wound healing after skin cancer surgery with Mohs micrographic surgery (MMS) in the face in a randomized controlled trial comparing autologous patch healing versus secondary intention healing.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Clinical Measurement of Transepidermal Water Loss.
Kundu D, Jayaraman A, Sen CK. · · 2026 · cited 4× · PMID 40476522 · DOI 10.1089/wound.2024.0148
Autologous Patch Healing vs Secondary Intent Healing after Mohs Micrographic Surgery: A Randomized Controlled Trial.
Hjorth MK, Burian EA, Karlsmark T, Mogensen M, et al · · 2026 · PMID 42051021 · DOI 10.2340/actadv.v106.43586

Verify or expand the search:

Other recruiting trials for Skin Cancer

Currently open trials in the same condition.

NCT07288073 — TIL Therapy in cSCC and MCC · Phase 2 · recruiting
NCT06926075 — Early Phase Study of KESONOTIDE™in Participants With Solid Tumours · Phase 1, PHASE2 · recruiting
NCT06932172 — Artificial Intelligent Decision Support for Skin Cancer Diagnostics in Primary Care · NA · recruiting
NCT07510061 — Title: ICARUS - Psycho-physiological Profiling of Low and High Heat-resilient Individuals · NA · recruiting
NCT07200544 — Meloxicam in Mohs Micrographic Surgery · Phase 4 · recruiting

Other Bispebjerg Hospital trials

Trials by the same sponsor.

NCT06872060 — The Effects of Glucagon on Renal Regional Blood Flow in Humans Measured by Magnetic Resonance. · NA · not yet recruiting
NCT07373587 — Preventing Hospital Associated Disability in Older Patients: Individualized Nutrition and Exercise Strategy · NA · not yet recruiting
NCT07123558 — Anal Cancer Prevention in High-Risk Categories of Men Who Have Sex With Men · NA · not yet recruiting
NCT07124338 — Preventing Hospital Associated Disability in Older Patients: Individualized Nutrition and Exercise Strategy, a Feasibili · NA · active not recruiting
NCT07096648 — Alert Burden When Monitoring Patients at Home · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05170035 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bispebjerg Hospital
Last refreshed: 15 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05170035.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing